Po‐Han Lin
Impact in
- Cancer Research top 10%
- Cancer Genomics and Diagnostics
- Oncology top 10%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
Papers in
- Oncology 16
- HER2/EGFR in Cancer Research 5
- PARP inhibition in cancer therapy 5
- Cancer Treatment and Pharmacology 2
-
- DNA Repair Mechanisms 8
- Co-authors
- Yau‐Huei Wei (1 shared paper)Shih-Huang Lee (1 shared paper)Chiun‐Sheng Huang (8 shared papers)Sung‐Hsin Kuo (5 shared papers)Ching‐Hung Lin (5 shared papers)Andrew Krivoshik (2 shared papers)Bertrand Tombal (2 shared papers)D. Phung (2 shared papers)
- Journals
- Oncotarget (3 papers)Annals of Oncology (2 papers)Frontiers in Oncology (2 papers)PLoS ONE (2 papers)Scientific Reports (1 paper)
- Partner nations
- TaiwanUnited StatesFrance
In The Last Decade
Po‐Han Lin
36 papers receiving 777 citations
Peers
Comparison fields: 5 of 82
- Cancer Research 219
- Oncology 263
- Pulmonary and Respiratory Medicine 208
- Genetics 135
- Hematology 50
Countries citing papers authored by Po‐Han Lin
This map shows the geographic impact of Po‐Han Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Po‐Han Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Po‐Han Lin more than expected).
Fields of papers citing papers by Po‐Han Lin
This network shows the impact of papers produced by Po‐Han Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Po‐Han Lin. The network helps show where Po‐Han Lin may publish in the future.
Co-authors
The 25 scholars most cited alongside Po‐Han Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 120 | |
| 2 | 2017 | 71 | |
| 3 | 2016 | 69 | |
| 4 | 2017 | 49 | |
| 5 | 2018 | 49 | |
| 6 | 2012 | 34 | |
| 7 | 2017 | 32 | |
| 8 | 2020 | 31 | |
| 9 | 2021 | 29 | |
| 10 | Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer. | 2014 | 26 |
| 11 | 2013 | 25 | |
| 12 | 2019 | 25 | |
| 13 | 2016 | 23 | |
| 14 | 2021 | 22 | |
| 15 | 2012 | 18 | |
| 16 | 2016 | 17 | |
| 17 | 2016 | 16 | |
| 18 | 2010 | 15 | |
| 19 | 2011 | 14 | |
| 20 | Evaluation of breast cancer susceptibility loci on 2q35, 3p24, 17q23 and FGFR2 genes in Taiwanese women with breast cancer. | 2012 | 14 |
About Po‐Han Lin
Po‐Han Lin is a scholar working on Oncology, Molecular Biology, Genetics, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 38 papers that have together received 784 indexed citations. Recurring topics across this work include DNA Repair Mechanisms (8 papers), BRCA gene mutations in cancer (7 papers), HER2/EGFR in Cancer Research (5 papers), PARP inhibition in cancer therapy (5 papers), Genetic factors in colorectal cancer (3 papers), Breast Cancer Treatment Studies (3 papers), Ovarian cancer diagnosis and treatment (3 papers) and Cancer Treatment and Pharmacology (2 papers). The work is most often cited by research in Cancer Research (219 citations), Oncology (263 citations), Pulmonary and Respiratory Medicine (208 citations), Genetics (135 citations) and Hematology (50 citations). Po‐Han Lin has collaborated with scholars based in Taiwan, United States and France. Frequent co-authors include Yau‐Huei Wei, Shih-Huang Lee, Chiun‐Sheng Huang, Sung‐Hsin Kuo, Ching‐Hung Lin, Andrew Krivoshik, Bertrand Tombal, D. Phung, Tomasz M. Beer and Andrew J. Armstrong. Their work appears in journals such as Oncotarget, Annals of Oncology, Frontiers in Oncology, PLoS ONE and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.